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Introduction
Catheter ablation for AF has emerged as an alternative to 
antiarrhythmic drug (AAD) therapy after the failure of at least 
one AAD, or even as the first line of treatment in selected cases.1-3 
Although a wide variety of ablation techniques have been used 
to treat AF, it is generally agreed that the cornerstone of any 
transcatheter procedure is the electrical isolation of all PVs. This is 
currently most commonly achieved by encircling the PVs with focal 
RF lesions under the guidance of a 3D electroanatomical mapping or 
navigation system.4 This point-by-point ablation technique requires 
extensive operator experience for efficiency and safety, and is usually 
associated with long procedure times, especially in centers with 
limited experience. Novel methods aiming at simpler and faster PVI 
have therefore been developed in recent years, including balloon-
based technologies.
Cryoballoon (CB) ablation was the first introduced5-6 and continues 
to be utilized routinely in many centers. The laser balloon has also 
been accepted and is becoming used increasingly in even more 
laboratories.7 Only limited clinical data are available with the ”hot” 
RF balloon,8 while the high-intensity focused ultrasound balloon has 
been removed from clinical practice after lethal complications.9 The 
common concept of these ”single-shot” AF ablation technologies is 
the creation of circular lesions for PVI by placing the ablation device 
at the antrum or ostium of the PVs without the need for continuous 
repositioning. 
The phased RF ablation system was also designed to address 
many of the challenges associated with conventional focal catheter 
ablation. Specifically, the system utilizes anatomically designed, 
multi-electrode catheters with tissue temperature monitoring and a 
closed-loop power control generator to create contiguous, transmural 
lesions.10
Phased RF Ablation Technique
The phased RF AF ablation catheter family consists of 3 catheters 
(Fig. 1). 
The circular multipolar pulmomary vein ablation catheter (PVAC; 
Medtronic Inc, Minneapolis, MN, USA) was designed to create 
antral lesions of the PVs and provide distal mapping and pacing to 
assess PVI. The original version of the PVAC consisted of a 25-mm 
helical electrode array with 10 platinum electrodes and over-the-wire 
tracking for enhanced PV targeting and placement stability. Most of 
the published data reflect the experience with this device, which was 
recently replaced by the PVAC Gold catheter which contains 9 gold 
electrodes. Gold has more than 4 times better thermal conductivity 
than that of platinum, thereby providing faster cooling and more 
precise temperature control. The number of electrodes was reduced 
in order to eliminate the potential bipolar short circuit between 
electrodes 1 and 10, which did occur with the previous PVAC, as 
discussed later. Further, a 20-degree forward tilt was added to the 
distal circular segment of the new PVAC Gold catheter for a more 
uniform contact with the PV antrum.  
The multiarray septal catheter (MASC™, Medtronic Inc, 
Minneapolis, MN, USA) is designed to map and ablate the atrial 
septal wall. It has 12 platinum electrodes on the underside of the array, 
with fins for added cooling. After the MASC has been introduced 
through the transseptal puncture site, the electrodes are positioned 
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against the septum by pulling back on the catheter.
The multiarray ablation catheter (MAAC™, Medtronic 
Inc, Minneapolis, MN, USA) is designed to map and ablate 
arrhythmogenic drivers in the left atrial (LA) body, such as complex 
fractionated atrial electrograms (CFAEs). It is composed of 8 finned 
platinum electrodes affixed to an X-shaped nitinol frame, with 2 
electrodes on each arm. 
All three catheters monitor electrode-tissue temperature through 
thermocouples bonded directly to each electrode on the side of the 
electrode in contact with the tissue. Thermocouples are placed as 
close as possible to the tissue interface for more accurate temperature 
monitoring.
A unique feature of the system is the duty-cycled phased RF energy, 
which is used for lesion formation with all 3 catheters. The GENius™ 
Multi-Channel RF Ablation Generator (Medtronic, Minneapolis 
MN, USA) contains 12 independently controlled RF generators for 
each electrode in the catheter. It monitors the temperature on each 
electrode and adapts the power to achieve and maintain the target 
temperature (nominally 60 °C). Power regulation is achieved through 
duty-cycling of the RF energy, rather than voltage control (Fig. 2.) 
The time period with no RF delivery, allows accurate temperature 
monitoring and provides time for the electrode to cool between RF 
bursts. The multi-electrode catheter design and the generator facilitate 
simultaneous bipolar (between the electrodes) and unipolar (from the 
electrode to the ground pad) delivery of energy (Fig. 3). Unipolar RF 
delivery results in deeper lesions, while bipolar application facilitates 
lesions between electrodes. The generator allows the operator to 
select between different ratios of simultaneous unipolar and bipolar 
energy delivery including unipolar only, 1:1, 2:1, 4:1, or bipolar only. 
For example, the 4:1 energy mode indicates that 80% of the energy 
delivered is bipolar and the remaining 20% is unipolar. The results of 
bench tests indicated that the depth of the lesions was proportional to 
the energy mode selected, with unipolar delivery causing the deepest 
lesions, followed by 1:1, 2:1, 4:1 and bipolar RF application, the latter 
causing the shallowest lesions.11 The GENius™ monitors the power 
and the temperature on each electrode and displays to the operator 
when the power and temperature are sufficient to create a good lesion 
(Contact IQ). The bars are yellow if the temperature or the power is 
too low to cause a lesion, and green when the power and temperature 
are sufficient for better lesion creation (>3 W and > 50 °C) which has 
been associated with a better clinical outcome.
Phased RF ablation procedures require a single transseptal puncture 
and a standard or a stearable transseptal sheath to guide the ablation 
catheter. Recent recommendations on periprocedural anticoagulation 
include uninterrupted vitamin K antagonist (VKA) administration 
for at least 1 month before the procedure and a therapeutic (2-3) 
INR on the day of the ablation. A heparin iv bolus is administered 
before or immediately after the transseptal puncture and repeated 
as required to reach and maintain a target INR level above 350 sec 
throughout the left atrial access period.  
The PVAC or PVAC Gold catheter is used to isolate and then 
validate the elecrical isolation of all PVs. The catheter is introduced 
into the sheath with the spiral array extended over a guidewire 
(0.032 inches in diameter, at least 180 cm in length) through use of a 
sliding knob on the catheter handle. Passing the valve of the sheath 
is facilitated by a tube-shaped capture device provided with the 
catheter. It is recommended to capture the 3-dimensional distal part 
containing the electrodes under saline in order to eliminate any air 
bubble possibly trapped within the complex structure of the electrode 
array. The catheter is advanced through the guiding sheath over the 
guidewire positioned in one of the PVs. When it enters the LA, the 
sliding knob is retracted to allow the electrode array to regain its 
circular shape. Positioning the electrodes at the PV antra is facilitated 
by the guidewire in the PV being advanced beyond the border of the 
cardiac silhouette, which also promotes the maintenance of a stable 
Figure 1: The phased RF catheter family and the GeniousTM RF generator. 
See text for details. (Image courtesy of Medtronic Inc)
Figure 2:
Duty-cycling of RF energy. While continuous RF energy is delivered 
during conventional RF ablation, “on” and “off” periods alternate 
during duty-cycled ablation. The length of the “on” time is 
regulated to reach and maintain the target temperature. The time 
period with no RF delivery allows accurate temperature monitoring 
and provides time for the electrode to cool between RF bursts. 
(Image courtesy of Medtronic Inc)
Figure 3:
The concept of unipolar and bipolar energy delivery (phasing). 
The multi-electrode catheter design and the generator enable 
simultaneous bipolar (between electrodes) as well as unipolar 
(from electrode to ground pad) delivery of RF energy. There is no 
voltage difference thus no current flow between neighbouring 
electrodes while “in phase”, so only unipolar energy is delivered 
between each electrode and the ground pad (left). When the 
voltages for the two adjacent electrodes are “out of phase” (right), 
interelectrode voltage difference results in bipolar RF delivery. 
Different ratios of simultaneous unipolar and bipolar energy 
delivery including unipolar only, 1:1, 2:1, 4:1, or bipolar only can be 
selected. (Image courtesy of Medtronic Inc)
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position during RF deliveries. PV angiography through the guiding 
sheath can be used to assess the catheter position in relation to the 
ostium so as to avoid any RF application inside the PVs. Catheter 
placement with stable tissue contact on as many electrodes as possible 
as assessed via the electrogram is preferred. RF energy is applied for 
60 sec, usually with a starting bipolar:unipolar ratio of 4:1 or 2:1. It 
is recommended to switch off any electrode pair that fails to reach at 
least 50 oC during RF delivery in order to in order to avoid ineffective 
applications due to improper contact at the electrode-tissue interface. 
Furthermore, when an electrode reaches the target temperature while 
delivering very low power (1-2 W), it is considered a sign of an 
undesirably strong electrode-tissue contact or a wedge position of 
the electrode, and energy delivery to that particular electrode should 
be switched off. 
As electrograms can not be assessed during the delivery of phased 
RF current because of electrical noise, electrical conduction of the 
PVs can be assessed between the applications. It is inherent to the 
electrode design that the intracardiac signals recorded with this 
circular catheter are smoothed, less detailed and lower in amplitude 
than those recorded with conventional circular mapping catheters 
(Fig. 5). Duytschaever reported a 93% overall diagnostic accuracy 
for the verification of PVI when a conventional mapping catheter 
was used as a gold standard.12 Pacing maneuvers or a conventional 
mapping catheter should be considered whenever doubt remains 
about PV conduction.13
Besides PVI, phased RF ablation of atrial tissue at sites 
demonstrating CFAEs can be performed through use of the MASC 
and MAAC devices. The MASC is designed to ablate the septum in 
response to pulling on the catheter and the transseptal sheath and 
holding the electrode against the septum. Between RF applications 
the catheter can be rotated to cover another area of the septum. The 
MAAC catheter is designed to ablate other sites of the LA, including 
the posterior wall.   
A significant limitation of current phased RF technology is that due 
to the many anatomical variations it may be difficult to have a stable 
tissue contact with these multipolar catheters even after different 
kinds of maneuvers. Recent data suggest that the inclusion of contact 
force sensors significantly improves reliability and safety therefore 
this technology is now considered by many electrophysiologists as 
the gold standard for left atrial ablation. Phased RF ablation will 
likely be of greater interest once it has this extra function.
Clinical Results with Phased RF Ablation
Acute Success and Procedural Parameters
Procedural outcomes and follow-up results from some single-
center studies are presented in Table 1.14-24 On the basis of a 
metaanalysis of 42 publications, Andrade et al.25 reported an average 
procedure time of 116.9±33 min and a fluoroscopy time of 26.5±9.6 
min with 25.1±3.4 applications per procedure on use of the PVAC 
only in patients with paroxysmal AF. Procedure and fluoroscopy 
times for ablations with the PVAC, MASC and MAAC in persistent 
AF patients were 137.1±29.3 and 31.6±12.4 min, respectively. The 
data on 1147 patients from 20 studies indicated that acute PVI was 
achieved with the PVAC alone, without concomitant use of a focal 
RF ablation catheter, in 98.57% of the patients and in 99.38% of the 
targeted PVs. It should be noted that mean procedure times below 
85 min have been reported from experienced centers for a cohort of 
paroxysmal14 or mostly paroxysmal AF patients.15
Longer-Term Outcome
Scharf et al. reported results of a survey on 2748 patients treated 
with phased RF ablation for mostly paroxysmal AF in 20 European 
centers.26 In 1669 paroxysmal AF patients, the overall, the first 
procedure and the AAD-free success rates during a mean follow-
up of 11.2 months were 82% 58% and 59% respectively. Similar 
results were reported from a high-volume center:22 arrhythmia-free 
survival after a single procedure without AAD in 120 paroxysmal AF 
patients was 55% at 1 year and 49% at 2 years. In another analysis by 
the same group,21 the PV anatomy did not have a significant effect on 
the long-term results; only a tendency to a poorer outcome was seen 
for PVs with diameters > 24 mm. 
The Tailored Treatment of Persistent Atrial Fibrillation (TTOP-
AF) trial, a randomized, multicenter study involving 210 patients 
with persistent AF, compared the effectiveness and safety of phased 
RF ablation with AAD.27 All the patients in the ablation group were 
treated with the PVAC, the MASC and the MAAC. The chronic 
Figure 4:
The PVAC and the PVAC Gold positioned in the pulmonary veins. 
PVAC Gold (9 electrodes) is positioned in the lateral, PVAC (10 
platinum electrodes) in the septal pulmonary veins. Note the 
overlap between poles 1 and 10 of the PVAC in the right inferior 
vein and a „safe” interelectrode distance in the right superior vein 
(arrows). See text for explanation
Figure 5:
Pulmonary vein potentials recorded by the PVAC from the 
left superior pulmonary vein during continuous stimulation 
in the coronary sinus. Pacing artefacts are followed by atrial 
electrograms and pulmonary vein potentials (*)
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by electroanatomical mapping (Table 2) in a number of single-center 
studies.29-38 Significantly lower procedure times were consistently 
reported with phased RF, while the fluoroscopy times were similar 
or also shorter when the PVAC was used. No difference in efficacy 
was reported in these trials which involved relatively small numbers 
of patients and a variable length of follow-up. A comparison of the 
results of the worldwide survey39 of procedures in which focal RF 
ablation was performed in the majority of patients with the data from 
the European Survey on phased RF ablation26  likewise suggests a 
similar outcome with the two techniques. In the first randomized 
multicenter trial in which PVI with electroanatomically guided wide-
area circumferential ablation (WACA; 92 patients) was compared 
with use of a focal irrigated RF catheter (94 patients), the AF-free 
survival at 12 months was 56% and 60% respectively.38 Both the 
procedure time and the fluoroscopy time were significantly shorter 
with the PVAC. 
A comparison of these 2 technologies as the initial experience with 
AF ablation in a lower-volume center has also been reported.30 The 
first 109 patients undergoing PVI at this center were randomized 
for 3D mapping-guided focal RF or for phased RF ablation. The 
6-month success rate was significantly higher with the PVAC (68%) 
than with focal ablation (39%), while the complication rates were 
similar. The procedure and fluoroscopy times were also significantly 
shorter with phased RF ablation. Although the number of these 
patients is limited, these data suggest that the influence of operator 
experience on the clinical success and procedural complications may 
be less significant during PVI with the PVAC as compared with focal 
RF ablations.
Complications with Phased RF Ablation
Cerebral Embolization
The risk of cerebral embolization arose as a significant concern 
relatively early after this technology was introduced in clinical 
practice. The TTOP-AF40 study demonstrated a 2.3% acute stroke 
rate (4/176) in all ablated patients and a per-procedure incidence of 
1.7% (4/239). Although the study was published only in 2014, data 
were presented to the Food and Drug Admininstration in 2011, and 
the results therefore received publicity earlier. It is noteworthy that 
strokes occurred within 12 hours postablation on a subtherapeutic 
INR level in all the patients in the TTOP-AF study suggesting that 
effectiveness criterion (defined as the acute isolation of all PVs, a 
50 % reduction of CFAE targets, restoration of stable SR at the 
end of the ablation, and a > 90% reduction in the cumulative atrial 
arrhythmia (atrial flutter or AF lasting > 10 minutes) time on the 48-
hour monitor 6 months postablation as compared with the baseline 
in the absence of AAD therapy was met in 57.6% of the patients. In 
the 620 patients treated for persistent/long-standing persistent AF 
in the European survey.26 the overall, first procedure and AAD-free 
success rates at 11.2 months postablation were 70%, 58% and 58%.
The efficacy data of the European survey were also analyzed with 
respect to the level of experience of the centers reporting the data. 
Importantly, the overall and first procedure success rates were similar 
among the higher (79.1% and 68.8%) and lower volume (79.4% and 
72.3%) centers. However, a poorer success rate was reported off AAD 
in the lower- volume centers (49.7%) than in the higher-volume 
centers (60.8%). Further, the success rates did not either depend 
on the duration of experience with phased RF ablation or on the 
number of phased RF procedures performed. Our group reported 
similar findings:28 neither the success rate nor the complication rate 
differed during the 1st, the 2nd and the 3rd 44 patients treated with 
phased RF ablation at our center.
PVAC Ablation Outcomes in Comparison with Focal RF Ablation
PVAC ablation has been compared with focal RF ablation guided 
Figure 6:
Incidence of silent cerebral lesions detected by DW MRI in different 
studies with cryoballoon (blue), irrigated RF (yellow) and phased RF 
(blue)
Table 1: Acute and longer-term results of phased RF ablation
Study No.of 
Pts
Age Type of AF parox: 
persistent (%)
Mean Left atrial 
diameter(mm)
Proc. time 
(min)
Fluoro time   
(min)
Additional 
ablation 
Acute success 
rate (%)
Months of FU Long term 
success (%)
Boersma et al. 14 98 59±9 100:0 na 84±29 18±9 - 100 6 83
Fredesrdorf et al.15           21 59±12 80:20 na 81±13 30±11 - 99 6 86
Scharf et al. 16         50 58±7 long-standing 
persistent
46±5 155±40 55±35 MASC+MAAC 100 6.3±0.9 70
Beukema et al.17          102 57.9±9.6 90:12 41.2±6.5 139.3±37.72 32.1±11.3 irrigated RF if 
needed
100 12.2±3.9 60.8
Wieczorek et al.18  88 58±11 100:0 44±4 125±28 21±13 RF 99 >3 and <12 ≥12 82.2       79.2
Duytschaever et al. 19 77 60±8 100:0 41±4 176±25 na - 97 3 74
Wieczorek et al. 20            73 56±12 100:0 44±3 122±27 20±11 RF if needed 99 6 85           
Mulder et al. 21      89 59±8 long-standing 
persistent
42±4 112±32 21±10 MASC+MAAC 100 12 49
Mulder et al. 22        120 59 100:0 40±5 86±26 na - 100 24 49
Mulder et al. 23            100 59±9 100:0 40±5 na na - 100 12 53
Nardi et al. 24 429 60±12 68:32 na 62±15 na 75 patients had 
2 procedures
na 22±5 68.5
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of 42 papers which included the data on 1162 patients treated for 
paroxysmal and 347 patients with persistent AF, the incidence of 
thromboembolic complications was 0.63%, including 6 strokes, 2 
TIAs and 2 myocardial infarctions.25 In the prospective multicenter 
trial in which electroanatomically guided WACA was compared with 
PVAC ablation, 2 strokes (2%) occurred in the latter group, both 
within 48 hours after the ablation, with heparin-bridging strategy 
applied in both.38 
Besides clinically manifest strokes, AF ablation might also result in 
a clinically silent cerebral embolism. Silent cerebral ischemia (SCI) 
can be detected by diffusion-weighted (DW) magnetic resonance 
imaging (MRI) after the ablation procedure.41-46 The SCIs frequently 
appear at multiple locations which are not related to a certain vascular 
territory but represent different vascular distributions, suggesting the 
embolic nature of these lesions. The reported rate of postablation SCIs 
is highly variable, ranging from 1.7% (11) to 38.9%. In the earlier 
publications, a significant correlation was demonstrated between the 
incidence of these lesions and the ablation technology, with phased RF 
ablation consistently posing the highest risk.  Siklódy et al. reported 
not necessarily the ablation technology per se, but rather inadequate 
anticoagulation may possibly have contributed to these cerebral events. 
The results of the recently published COMPARE40 trial underscores 
the critical importance of periprocedural anticoagulation: point-
by-point RF antrum isolation with or without CFAE ablation was 
associated with a symptomatic periprocedural thromboembolic event 
rate of 4.9% when warfarin was discontinued with heparinbridging 
as compared with a 0.33% event rate on uninterrupted warfarin 
therapy. The majority of thromboembolic events occurred in non-
paroxysmal AF patients. Following the completion of the TTOP-AF 
study, more favorable safety results were published by a center with 
extensive experience in phased RF ablation: 2 strokes and 5 transient 
ischemic attacks (TIAs) occurred during 662 procedures (with 
use of the PVAC alone in the majority of procedures) in patients 
with paroxysmal and persistent AF.22 Cerebral ischemic events also 
occurred within 24 hours postablation in this study in 6 of the 7 
patients, the INR during the procedure was <2.0 in 3 of them. In 
the European survey on phased RF ablation in 2748 patients, a total 
stroke and TIA incedence of 1,1% was reported.26 In a metaanalysis 
Figure 7:
Cerabral microembolization during pulmonary vein isolation with different ablation technologies. Left: A plot of the mean number of 
microembolic signals (MES) recorded by transcranial Doppler (TCD) in the middle cerebral artery in each treatment group as compared 
with the cryoballoon (CB) group. Besides CB and nMARQ, a novel circular multipolar irrigated RF technology, 3 different phased RF 
methods were compared with respect to cerebral microembolization: phased RF with the older ablation generator (PVAC I), phased RF with 
avoiding distal PVAC poles to come in close proximity (PVAC II) and phased RF with newer software generation which contains a special 
contact detection algorythm to avoid tissue overheating in improper contact scenarios and do not permit simultaneous use of distal PVAC 
electrodes (PVAC III). Right: Mostly gaseous microemboli were detected with different technologies. (Kiss et al [58]; reproduced with 
permission).
Table 2: Phased RF ablation outcomes in comparison with focal RF ablation
Study No.of Pts Age Paroxysmal: Persistent: 
Long standing    AF (%)
Left atrial 
diameter (mm)
Procedure 
time    (min)
Fluoro time    
(min)
Acute success 
rate (%)
Length of FU Long term 
success (%)
Bulava et al. 29 PVAC: 51                 
RF+ Carto: 51
56.5±9.9 
59.8±11.9
paroxysmal 41.2±5.4 
39.7±4.4
107±31 
208±46
16±5    
28±8
98          
98.5
202±13 days 77             
71
Choo et al.30 PVAC: 38   
RF+Carto:  
47 RF+NavX: 24     
RF+3D Mapping: 71
56.9±10.2 
56.2±10.5 
62.2±7.7 
58.2±10.2
79:2:0       
60:40:0       
63:37:0      
39:61:0
42.0±7.5 
40.5±7.5 
43.9±6.3 
41.5±7.3
168±41 
246±60 
265±60 
252±60
39±14 
73±27 
79±25 
75±26
97          
96        
100        
97
6 months 68             
40             
38             
39
Bittner et al. 31 PVAC: 40                
RF+3D Mapping: 40
57±11    
59±9
53:47:0       
58:42:0
43±5  
42±7
171±40 
224±27
26±8    
35±9
99        
100
254±99 days 72             
68
Khaykin et al. 32  PVAC: 31            
RF+3D Mapping: 19
63±10 
57±12
paroxysmal 39±6  
43±4
125±25 
135±26
36±14 
50±16
na      
na
6 months 67             
54
Spitzer et al. 33 PVAC: 388               
RF+NavX:151
61.7±9.7 
58.1±9.3
79.9 :17.5: 2.6 
54.3 :31.1:14.6
42±6  
43±5
67.0±18.0 
142.2±35.0
15.6±5.7 
29.3±9.8
>99 
>99
24months 64.2       
48.2
De Greef et al. 34 PVAC: 79   
RF+Carto: 82
60±10  
58±10
66:34:0 
55:45:0
41±7  
42±7
121±41 
169±43
33±11 
32±15
100 
100
3 years 65             
55
Tivig et al.35         PVAC: 143              
PVAC: 66       
RF+NavX :155   
RF+NavX:56
61±10  
61±10 
58.8±10 
61±9
paroxysmal 
persistent 
paroxysmal 
persistent
40±6  
46±6  
40±5  
47±7
128±38 
171±39 
134±43 
161±44
29±13 
46±14 
39±20 
44±18
na       
na      
na       
na
12months 76             
55             
71             
52
Looi et al.36    PVAC: 75 
RF+Carto: 128
60±10.1 
56.3±10.6
paroxysmal 48±4.2 
44.2±5.6
135±54 
178±43
46±29 
48±23
na       
na
268±176 days 
266±184 days
65.3 
65.6
Gal et al.37            PVAC:230  
RF+Carto: 230
56.6±10.3 
56.1±9.8
83.9:16.1 80:20 41.7±4.7 
40.6±4.9
133.9±38.8 
177.7±48.7
31.9±12.3 
29.7±12.3
99.8 
99.6
43 months 47.7 
45.5
McReady et al. 38 PVAC:94
RF+Carto or NAVx: 94
58±12
62±11
paroxysmal 38±7  
39±5
140±43 
167±42
35±16 
42±20
98
97     
12months 60
56
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RF generator has also been modified in recent years. An improved 
energy titration algorithm was implemented which regulates the 
power delivery to control the maximum, instead of the average 
temperature, with a target of 60 °C. Further, this software ensures a 
gradual and limited increase (4 W/s) during variable or intermittent 
electrode-tissue contact, thereby avoiding high temperature peaks. 
The importance of the catheter-tissue contact has been stressed since 
the introduction of contact force measurement for focal RF ablation 
catheters.56 With multipolar ablation, this becomes even more critical, 
as the maintenance of good contact simultaneously on multiple 
electrodes can be challenging, and the possibility of direct contact 
force measurement with this technology is not yet available. This 
concept is supported by our previous study: an analysis of temperature 
and power data obtained at high-resolution sampling from the 
GENius generator demostrated increased microembolus formation 
during intermittent contact scenarios when low temperature was 
compensated by increased power, which resulted in a temperature 
overshoot when the contact was re-established.57  Further, in the 
most recent issue of the GENius software, RF delivery is limited 
to 9 electrodes, thereby providing a definite solution regarding the 
problem of E1-E10 interaction.
Similarly to the trend observed in recent DW MRI studies on the 
rate of new SCI lesions after phased RF ablation, our group observed 
a significant decrease in the number of cerebral MESs detected by 
TCD.58 A Comparison of cerebral microembolization during PVAC 
ablations before and after the procedural changes discussed above 
were implemented at our center revealed a significant decrease to 
the level obtained with a CB (Fig. 6). The significant reduction 
in microembolization with phased RF was clearly related to the 
elimination of the MESs during the energy delivery period of the 
procedure. It is noteworthy that the MESs were largely gaseous in 
nature in all the treatment groups.
Other Complications
Other potential complications during phased RF ablation are 
similar to what may occur during left atrial ablation with any other 
technology and include problems at vascular access sites, pericardial 
tamponade and PV stenosis. 
In the meta-analysis by Andrade et al., 3 pericardial tamponades 
and 3 effusions were reported in 1719 patients; 1 out of 931 patients 
exhibited symptomatic PV stenosis.25 A higher incidence of PV 
stenosis at long-term follow-up emerged in a recent study.59  A 
25-50%-degree stenosis was found in 37%, one of 50-70 % in 9% 
and one of > 70% in 3% of the patients. However, these mostly mild-
to-moderate narrowings resulted in no symptoms and ventilation/
scans demonstrated no abnormalities. Clinically relevant injury to 
the esophagus, one of the most feared complications of AF ablation 
with high mortality and phrenic nerve palsy, has never been reported 
with phased RF ablation.
OngoingTrials with Phased RF Ablation
The PRECISION GOLD Study is a prospective multi-center 
trial, the main objective of which is to evaluate the incidence of 
asymptomatic cerebral lesions after PVI using the new PVAC Gold 
for PVI in patients with paroxysmal AF. The trial was completed last 
year and full-length publication is expected during 2015.
The ongoing VICTORY AF (ClinicalTrials.gov Identifier: 
NCT01693120) is a prospective global, multi-center, single-arm, 
controlled, unblinded, investigational clinical study, with the purpose 
of  evaluating the risks of procedure and/or device-related strokes 
an SCI incidence of 33% in 24 AF patients after ablation with the 
PVAC, as compared with 7.4% and 4.3% in those ablated with focal 
irrigated RF and the CB technology, respectively.44 Similarly, Gaita et 
al. found a significantly higher SCI rate after PVAC ablation (38.9%) 
as compared with irrigated RF or CB (8.3% and 5.6% respectively)45 
Although 2/3 of the lesions were at most 3 mm in diameter and 
the majority, (especially the smaller ones) disappeared within days 
or weeks after ablation,47 the phenomenon generated significant 
concern as regards the potential long-term consequences on the 
cognitive function of these patients.48-49 In line with the MRI results, 
intraoperative transcranial Doppler (TCD) detection of cerebral 
microembolization also indicated a technology-related difference: 
our group recorded a significantly higher number of mostly gaseous 
microembolic signals (MESs) during PVI with the PVAC than with 
CB.50  It may be noted that the majority of MESs were associated 
with the energy delivery phase of PVAC ablations, while a relatively 
even distribution was demonstrated during CB ablation.
Lower SCI rates have been reported with the phased RF 
technology in more recent publications,51-52 and a cerebral lesion was 
demonstrated in only 1 of 60 patients in the ERACE multicenter 
trial, which enrolled patients with paroxysmal AF who underwent 
PVI with the PVAC.53 The significant reduction achieved in clinically 
silent microembolization as demonstrated by these DW MRI studies 
might be attributed to the strict periprocedural anticoagulation, 
including the use of uninterrupted VKA before the procedure and 
heparin administration to reach an ACT target > 350 sec during 
ablation. Further, on the basis of the preclinical data, refinements 
in specific technical elements of the phased RF ablation have been 
implemented. In an animal model, Haines observed significantly 
enhanced microembolization with blended unipolar:bipolar energy 
delivered through PVAC electrodes in close proximity to each 
other, which was a likely common scenario, thanks to the squeezed 
position of the distal PVAC loop.54-55 While actual physical contact 
between any two electrodes results in an electrical short circuit and 
the termination of RF delivery, a reduced interelectrode distance (less 
than the fixed 3 mm between two neighboring electrodes mounted 
on the distal circular segment of the PVAC) without contact may 
lead to blood and tissue overheating, due to a high current density 
during the RF delivery. Simple measures to avoid this possibility 
include a careful fluoroscopic assessment of the electrode positions, 
exclusion of simultaneous RF delivery to electrodes 1 and 10, and a 
software modification implemented in the GENius generator, which 
supports simultaneous RF delivery to a maximum of 9 electrodes. 
In keeping with this concept, the number of electrodes on the new 
PVAC Gold catheter is limited to 9. Animal data also pointed to 
a tendency for more microemboli with more bipolar RF delivery. 
It is therefore reasonable to change the earlier practice of starting 
the energy delivery in 4:1 bipolar:unipolar mode at each PV, and 
begin with a 2:1 ratio, the current practice in most centers. The 
animal model also revealed that the introduction of air into the LA 
via the transseptal sheath potential was a potential source of gaseous 
emboli. A significantly larger air volume was measured during the 
introduction of the PVAC, possibly because of its more complex 
shape as compared with that of a conventional focal RF catheter. 
To prevent air entrapment, submerged capture of the electrode 
array in a saline bath prior to insertion into the FlexCath sheath is 
recommended. 
Besides the procedural changes described above, the GENius 
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Conclusion
Phased RF ablation involves the use of anatomically designed, 
multi-electrode catheters with tissue temperature monitoring and a 
closed-loop power control generator to create contiguous lesions in a 
simpler procedure as compared with conventional AF ablation. The 
majority of the literature data relate to PVI with the PVAC in patients 
with paroxysmal AF. Similar acute and longer-term success rates, 
but significantly lower procedure and fluoroscopy times with PVAC 
ablation have consistently been reported relative to other AF ablation 
methods. The incidence of manifest and silent cerebral complications 
has fallen significantly in recent reports, thanks to important 
changes in the periprocedural anticoagulation regime, procedural 
modifications and improvements in software regulations of the RF 
generator. Evaluation of the new PVAC Gold catheter is currently in 
progress. Data from some studies suggest a short learning curve and 
favorable results with this technology, even in lower-volume centers 
and in the hands of operators with limited experience in AF ablation. 
The safety and efficacy outcomes of phased RF ablation, including 
mapping and ablation of arrhythmogenic drivers in the LA, body in 
addition to PVI in patients with persistent AF are currently being 
evaluated in the ongoing VICTORY AF trial.
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